Drug Shortage Report for NUCALA
Report ID | 130613 |
Drug Identification Number | 02492989 |
Brand name | NUCALA |
Common or Proper name | Mepolizumab Injection |
Company Name | GLAXOSMITHKLINE INC |
Market Status | MARKETED |
Active Ingredient(s) | MEPOLIZUMAB |
Strength(s) | 100MG |
Dosage form(s) | SOLUTION |
Route of administration | SUBCUTANEOUS SUBCUTANEOUS |
Packaging size | PRE-FILLED AUTOINJECTOR x1 / AUTOINJECTEUR PRÉ-REMPLI x1 |
ATC code | R03DX |
ATC description | OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2020-12-18 |
Estimated end date | 2021-02-01 |
Actual end date | 2021-01-20 |
Shortage status | Resolved |
Updated date | 2021-01-21 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Company contact information | 1-800-387-7374 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v1 | 2020-12-22 | English | Compare |
v2 | 2020-12-22 | French | Compare |
v3 | 2020-12-22 | English | Compare |
v4 | 2020-12-22 | French | Compare |
v5 | 2021-01-20 | English | Compare |
v6 | 2021-01-20 | French | Compare |
v7 | 2021-01-21 | English | Compare |
Showing 1 to 7 of 7